Pantostad 40

Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.

Pack size Box of 14 tablets, 28 tablets, 30 tablets, 50 tablets
Shelf-life 36 months
Composition Pantoprazole
Dosage forms and strengths Enteric-coated tablet: 40 mg
Product code :



  • Gastro-oesophageal reflux disease (GERD).
  • Peptic ulcer disease.
  • Prophylaxis for NSAID-associated ulceration.
  • Zollinger-Ellison syndrome.


Gastro-oesophageal reflux disease (GERD):
20 – 40 mg once daily x 4 – 8 weeks.
Maintenance therapy: 20 to 40 mg daily.
Recurring therapy: 20 mg daily.

Peptic ulcer disease:

  • 40 mg once daily x 2 – 4 weeks (duodenal ulceration) or 4 – 8 weeks (benign gastric ulceration).
  • For the eradication of Helicobacter pylori: Pantoprazole (40 mg twice daily) + clarithromycin (500 mg twice daily) + amoxicillin (1 g twice daily) or metronidazole (400 mg twice daily).

Prophylaxis for NSAID-associated ulceration: 20 mg daily.

Zollinger-Ellison syndrome:
The initial dose is 80 mg daily, adjusted as required, up to 240 mg daily.
Daily doses greater than 80 mg should be given in 2 divided doses.

Hepatic impairment: Reduce dosage (maximum 20 mg daily) or use on alternate days (40 mg daily).

Renal impairment: A maximum dose of 40 mg daily.


Pantostad 40 is administered orally. Once-daily doses should be taken in the morning.

Known hypersensitivity to pantoprazole, any other ingredient in the formulation, or other substituted benzimidazoles (e.g., esomeprazole, lansoprazole, omeprazole, rabeprazole).

  • May increase the risk of gastrointestinal infections.
  • Common: Fatigue, headache; rash, urticaria; myalgia, arthralgia.
  • Elderly, patients at risk of osteoporosis or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (high doses and/or > 1 year).
  • Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric neoplasm. Pantoprazole may alleviate the symptoms and thus delay diagnosis.
  • Mild, transient elevations of serum ALT (SGPT).
  • Hypochlorhydria or achlorhydria may lead to malabsorption of cyanocobalamin.
  • Safety and efficacy in children younger than 18 years of age have not been established.
  • Pantostad 40 contains maltitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
  • Pregnant and nursing women (discontinue nursing or the drug).
  • Patients should be aware of how they react to drug before driving or operating machinery.